Literature DB >> 24924663

Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans.

Leslie Sibener1, Ibrahim Zaganjor1, Heather M Snyder1, Lisa J Bain2, Robert Egge3, Maria C Carrillo4.   

Abstract

By 2050, more than 13 million Americans of all ages are estimated to be living with Alzheimer's disease (AD), and the aggregate costs of care will swell to approximately $1.2 trillion. The rapidly climbing number of those affected with AD includes a growing population of aging military veterans affected who may have an added risk for the disease as a consequence of traumatic brain injury, posttraumatic stress disorder, and/or service-related injuries. The increasing number of individuals, the long duration of disability, and the rising cost of care for AD and other dementia to our society are important public health challenges facing many older adults. These challenges are further compounded by a burgeoning military veteran population that is much younger, with an increased risk of AD and other dementia, and who may experience decades-long periods of disability and care. This outlook underscores the critical need for investments in research at the federal and international levels to accelerate the pace of progress in developing breakthrough discoveries that will change the trajectory of AD and related dementia.
Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Healthcare costs; Military medicine; Posttraumatic stress disorder; Traumatic brain injury

Mesh:

Year:  2014        PMID: 24924663     DOI: 10.1016/j.jalz.2014.04.011

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  13 in total

Review 1.  Update on TBI and Cognitive Impairment in Military Veterans.

Authors:  Gregory A Elder
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 2.  Blast-related mild traumatic brain injury: a Bayesian random-effects meta-analysis on the cognitive outcomes of concussion among military personnel.

Authors:  Justin E Karr; Corson N Areshenkoff; Emily C Duggan; Mauricio A Garcia-Barrera
Journal:  Neuropsychol Rev       Date:  2014-09-25       Impact factor: 7.444

Review 3.  Military-related risk factors for dementia.

Authors:  Heather M Snyder; Roxana O Carare; Steven T DeKosky; Mony J de Leon; Derek Dykxhoorn; Li Gan; Raquel Gardner; Sidney R Hinds; Michael Jaffee; Bruce T Lamb; Susan Landau; Geoff Manley; Ann McKee; Daniel Perl; Julie A Schneider; Michael Weiner; Cheryl Wellington; Kristine Yaffe; Lisa Bain; Anthony M Pacifico; Maria C Carrillo
Journal:  Alzheimers Dement       Date:  2018-11-08       Impact factor: 21.566

4.  Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimer's Disease and Related Dementias.

Authors:  Brian Spencer; Robert A Rissman; Cassia Overk; Eliezer Masliah
Journal:  Methods Mol Biol       Date:  2022

5.  The Role of Nutrition and Inflammation on Cognition in a High-Risk Group for Alzheimer's Disease.

Authors:  Jordan M Jackson; Allison A Bay; Jolie Denise Barter; Liang Ni; William Michael Caudle; Monica C Serra; Whitney Wharton; Madeleine E Hackney
Journal:  J Alzheimers Dis Rep       Date:  2020-08-28

6.  Use of in-home activity monitoring technologies in older adult veterans with mild cognitive impairment: The impact of attitudes and cognition.

Authors:  Mira I Leese; Katherine E Dorociak; Madeline Noland; Joseph E Gaugler; Nora Mattek; Adriana Hughes
Journal:  Gerontechnology       Date:  2021-06

Review 7.  Dementia, post-traumatic stress disorder and major depressive disorder: a review of the mental health risk factors for dementia in the military veteran population.

Authors:  L A Rafferty; P E Cawkill; S A M Stevelink; K Greenberg; N Greenberg
Journal:  Psychol Med       Date:  2018-03-08       Impact factor: 7.723

8.  Supporting caregivers of veterans with Alzheimer's disease and traumatic brain injury: study protocol for a randomized controlled trial.

Authors:  Jennifer L Carnahan; Katherine S Judge; Joanne K Daggy; James E Slaven; Nicki Coleman; Emily L Fortier; Christopher Suelzer; Nicole R Fowler
Journal:  Trials       Date:  2020-04-19       Impact factor: 2.279

9.  Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.

Authors:  Brian Spencer; Sven Brüschweiler; Marco Sealey-Cardona; Edward Rockenstein; Anthony Adame; Jazmin Florio; Michael Mante; Ivy Trinh; Robert A Rissman; Robert Konrat; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2018-06-14       Impact factor: 17.088

10.  Underrepresentation of African-Americans in Alzheimer's Trials: A Call for Affirmative Action.

Authors:  Jaewook Shin; P Murali Doraiswamy
Journal:  Front Aging Neurosci       Date:  2016-06-03       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.